Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
J Thorac Oncol. 2021 Feb;16(2):205-215. doi: 10.1016/j.jtho.2020.10.006. Epub 2020 Oct 20.
J Thorac Oncol. 2021.
PMID: 33096270
Free article.
Review.